 BURLINGTON, Mass., Aug. 09, 2021 GLOBE NEWSWIRE -- Flexion Therapeutics, Inc. Nasdaq:FLXN announced that the results from the randomized, open-label, Phase 2 pharmacokinetic PK trial of ZILRETTA triamcinolone acetonide extended-release injectable suspension were published in Drugs in RD . The study compared the plasma PK profile of ZILRETTA to immediate-release triamcinolone acetonide in crystalline suspension TAcs and assessed the safety and general tolerability of ZILRETTA in osteoarthritis OA of the shoulder. 